A novel approach to synaptic protection in Alzheimer’s disease
info@cogrx.com
  • HOME
  • OUR COMPANY
    • ABOUT US
    • CogRx Team
  • Product Development
    • OUR SCIENCE
    • For Patients and their Families
  • NEWS & EVENTS
    • Press Releases
    • OUR EVENTS
    • CogRx in the news
  • Resources
  • CONTACT US
  • BUT THAT SHOULD NOT KEEP US FROM LIVING
    WE ARE ALL AGING....
  • Source: WHO Dementia Fact Sheet 2017
    60-70% OF DEMENTIA CASES MAY BE  DUE TO ALZHEIMER'S DISEASE,
    MAKING IT THE MOST COMMON FORM OF DEMENTIA
    NEARLY 47 MILLION PEOPLE WORLDWIDE HAVE DEMENTIA
    Text element
  • Source: WHO Dementia Fact Sheet 2017
    THAT'S ONE EVERY 3 SECONDS
    AROUND THE WORLD, THERE ARE NEARLY 10 MILLION
    NEW CASES OF DEMENTIA EVERY YEAR
  • BUT THAT SHOULD NOT KEEP US FROM LIVING
    BUT THAT SHOULD NOT KEEP US FROM LIVING
    WE ARE ALL AGING....

NEW TARGETS

Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Abeta oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.

Learn More

NEW DRUGS

The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Abeta oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.

Learn More

NEW HOPE

Very recent clinical advances using Abeta monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar ABeta, have demonstrated a reduction in Abeta burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Abeta approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.

Learn More

Latest News

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

PITTSBURGH, Feb. 12, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Pittsburgh, Jan. 04, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Pittsburgh, Nov. 08, 2017 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other



CogRx © 2017 All Rights Reserved. Terms of use and Privacy Policy

Designed & Developed by Infiyo

onhealthy.net